Collagen Peptide Supplementation Enhances Intramuscular Collagen Production in Men
A new RCT shows 15g daily of specific collagen peptides boosts intramuscular collagen Type I in healthy men, offering implications for formulation and market positioning within the sports nutrition segment.
London, United Kingdom — 08 July 2026
A recent randomised controlled trial (RCT) published by NutraIngredients Global indicates that specific collagen peptide supplementation significantly enhances intramuscular collagen Type I content in healthy men undergoing resistance training. The 12-week study involved 29 participants, all supplementing with 15 grams per day of BodyBalance, a particular collagen peptide formulation. Results showed a marked increase in intramuscular collagen Type I compared to a placebo group. Critically, this enhancement occurred without a concomitant rise in fibroblast numbers, suggesting that the peptides stimulated the activity of existing fibroblasts to produce more collagen, rather than increasing the cell count itself.
This finding underscores the role of targeted collagen peptides in supporting more effective connective tissue remodelling alongside high-load resistance exercise. The mechanism is likely attributed to the unique amino acid profile delivered by these specific peptides. The research reinforces that collagen supplementation serves as a complement to physical activity rather than a substitute. For ingredient suppliers and brand owners, this data provides a robust scientific basis for product development and claim substantiation, particularly within the competitive sports nutrition sector.
The study’s specificity on collagen type and dosage offers a valuable benchmark. It highlights that not all collagen products may yield identical results, necessitating careful ingredient selection for efficacy. The focus on healthy men engaging in resistance training also defines a clear target demographic, allowing for precise marketing strategies and product positioning.
What this means for United Kingdom
UK brand owners must pivot formulations towards specific collagen peptide types, similar to BodyBalance, to meet the 15g daily dosage demonstrated for efficacy. This research provides a robust scientific bedrock for ‘sport’ and ‘active lifestyle’ claims, allowing for differentiation in a crowded market worth over £100m annually. Manufacturers should prepare for increased demand for high-purity, hydrolysed collagen peptides and ensure robust traceability. Compliance teams can leverage these findings for stronger substantiation dossiers under FSA and MHRA guidelines, particularly for health claims related to connective tissue support. This creates a competitive edge against brands relying on more generic collagen offerings.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.